Pharmacological Optimization in Prevention in Heart Failure: A Sex-gap?

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 368 participants.

Also called NCT07295522

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 368 participants (planned count) (from the registry)
Sponsor
IRCCS Policlinico S. Donato (from the registry)
Registry
  • NCT NCT07295522
  • EudraCT 2025-520660-18
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07295522. Randomized; no masking; primary purpose treatment. Start 2026-03-31 (actual); primary completion 2027-06-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pharmacological Optimization in Prevention in Heart Failure: A Sex-gap?
Acronym
PopS-HF
Condition
Heart Failure
Condition
Acute Heart Failure
Condition
Heart Failure With Mildly Reduced Ejection Fraction
Intervention (Drug)
Guideline-Directed Medical Therapy (GDMT)
Lead sponsor
IRCCS Policlinico S. Donato (class: other)
Collaborator
Agenzia Italiana del Farmaco (class: other government)

Record details

Record id
cardio:ct-nct07295522
Content hash
9b59b36d682543ec95a3537f353613704137797e5267fa8ea497bc597b939b48